Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025New England Journal of Medicine

Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGilles LemesleRDRomain DidierPSPhilippe Gabríel Steg

Discussion

Loading...

Member takes

Overview

Randomized trial shows increased cardiovascular events in patients with chronic coronary syndrome, highlighting aspirin's risks alongside oral anticoagulation.

Key Points

  • Adding aspirin increased the risk of composite cardiovascular events compared to placebo.
  • In the aspirin group, 16.9% experienced primary efficacy outcomes versus 12.1% in the placebo group.
  • Overall mortality was significantly higher in the aspirin group at 13.4% versus 8.4% for placebo.
  • Major bleeding occurred more frequently in the aspirin group, at 10.2%, compared to 3.4% in placebo.

Cite This Study

Lemesle et al. (2025) studied this question.

synapsesocial.com/papers/68c23965b210217d6477b52dhttps://doi.org/10.1056/nejmoa2507532
View Full Paper
Ask AI
Bookmark
Share